SYRE
Spyre Therapeutics·NASDAQ
--
--(--)
--
--(--)
5.19 / 10
Netural
Fund flow is a standout strength with a 7.63/10 score, reflecting robust money inflows despite negative trends in block, small, medium, and extra-large flows; only large flows show a positive trend. Analyst coverage is limited to one institution (BTIG) but uniformly bullish (Strong Buy, 100% rating). Sentiment score is 5.19/10, neutral overall, aligning with the mixed signals from other pillars. This combination of strong liquidity and bullish analyst view partially offsets the weak fundamentals and technicals.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-16
InstitutionBTIG
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for SYRE?
- SYRE holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.19/10 (Netural).
